文献速递免疫规划

基于间日疟原虫AMA-1与MSP119的新型嵌合重组蛋白的制备、表征及免疫原性

Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP119.
PubMed 文献 · Vaccine · 2017-03-22

研究设计了一种含间日疟原虫裂殖子免疫优势域PvAMA166与PvMSP119的嵌合重组蛋白,在毕赤酵母中成功表达,并联合Poly(I:C)佐剂免疫BALB/c与C57BL/6小鼠。该嵌合蛋白在两株小鼠中均诱导针对两种蛋白的高抗体滴度,抗血清可识别成熟间日疟原虫裂殖体裂殖子上的天然蛋白,并在C57BL/6小鼠中诱导IFN-γ分泌细胞。作者认为该制剂应进一步在非人灵长类中开展临床前试验,作为间日疟疫苗的潜在候选。

要点

  • 嵌合蛋白PvAMA166-MSP119在毕赤酵母中成功表达,联合Poly(I:C)佐剂免疫两株小鼠。
  • 免疫后两株小鼠均产生针对两种蛋白的高抗体滴度,抗血清识别天然裂殖子蛋白。
  • 该抗原在C57BL/6小鼠中诱导IFN-γ分泌细胞,作者建议进一步开展非人灵长类临床前试验。

核心结论

  • 该含PvAMA166与PvMSP119的酵母重组蛋白因抗体滴度提高和细胞免疫应答而具有优势,应进一步在非人灵长类中开展临床前试验,作为间日疟疫苗的潜在候选。

研究设计与样本

  • 设计含间日疟原虫裂殖子免疫优势域PvAMA166与PvMSP119的嵌合重组蛋白,在毕赤酵母中表达。
  • 联合Poly(I:C)佐剂免疫BALB/c与C57BL/6两株小鼠,以ELISA检测抗体,并检测IFN-γ分泌细胞。

主要发现

  • 免疫后两株小鼠均产生针对两种蛋白的高抗体滴度(ELISA检测)。
  • 抗血清可识别成熟间日疟原虫裂殖体裂殖子上表达的天然蛋白。
  • 该抗原在C57BL/6小鼠中诱导IFN-γ分泌细胞。

临床怎么用

  • 作者认为该制剂应进一步在非人灵长类中开展临床前试验,作为间日疟疫苗的潜在候选。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Plasmodium vivax is the most widely distributed malaria species and the most prevalent species of malaria in America and Asia. Vaccine development against P. vivax is considered a priority in the global program for the eradication of malaria. Earlier studies have characterized the Apical Membrane Antigen 1 (AMA-1) ectodomain and the C-terminal region (19kDa) of the Merozoite Surface Protein 1 (MSP-1) of P. vivax as immunodominant antigens. Based on this characterization, we designed a chimeric recombinant protein containing both merozoite immunodominant domains (PvAMA166-MSP119). The recombinant PvAMA166-MSP119 was successfully expressed in Pichia pastoris and used to immunize two different mouse strains (BALB/c and C57BL/6) in the presence of the Poly (I:C) as an adjuvant. Immunization with the chimeric protein induced high antibody titers against both proteins in both strains of mice as detected by ELISA. Antisera also recognized the native proteins expressed on the merozoites of mature P. vivax schizonts. Moreover, this antigen was able to induce IFN-gamma-secreting cells in C57BL/6 mice. These findings indicate that this novel yeast recombinant protein containing PvAMA166 and PvMSP119 is advantageous, because of improved antibody titers and cellular immune response. Therefore, this formulation should be further developed for pre-clinical trials in non-human primates as a potential candidate for a P. vivax vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Rocha MV, Françoso KS, Lima LC, et al. Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP119. Vaccine. 2017. PMID: 28341111. doi:10.1016/j.vaccine.2017.03.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。